Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M

Autolus Therapeutics plc

Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.
Net loss $71.6M ($0.27 loss per share); cash equivalents $229.4M, down from $300.7M at Dec 2025.
Reaffirms FY2026 AUCATZYL net product revenue guidance $120-135M; expects continued positive gross margin.
Cost reduction: ~13% workforce cut; annualized savings ~$15M starting 2027; restructuring charges ~$8M.
Clinical pipeline on track: pediatric ALL data end-2027; lupus nephritis data 2028; progressive MS initial data end-2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Autolus Therapeutics plc reported first quarter ended March 31, 2026 results: revenue $26.2 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $26.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL)

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-26-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.